Responding to fraud in the Australian health, pharmaceuticals and medical devices sectors: a proposal for reform

Gregor Urbas, Thomas Faunce, Lesley Ann Skillen, Marcus Smith

Research output: Contribution to journalArticlepeer-review

Abstract

The risk of fraud within the Australian health, pharmaceuticals and medical devices sectors is significant,but more effective legal and regulatory responses than currently exist may be required for its detection and prevention. Looking at successful models from overseas jurisdictions may be of value. In particular, enhanced whistleblower protections and the qui tam litigation mechanism in the United States offer models for more effective anti-fraud measures. The model appears viable for local adaptation, but some legal, structural and cultural issues may need consideration and further research. This paper adopts the hypothesis that there is nothing intrinsic to the Australian legal system that would prevent the adoption of such mechanisms in Australia, and assesses the potential for these reforms to be introduced there.
Original languageEnglish
Pages (from-to)109-119
Number of pages10
JournalWorld Review of Business Research
Volume2
Issue number2
Publication statusPublished - 2012

Fingerprint

Dive into the research topics of 'Responding to fraud in the Australian health, pharmaceuticals and medical devices sectors: a proposal for reform'. Together they form a unique fingerprint.

Cite this